Your browser doesn't support javascript.
loading
Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation.
Rotz, Seth J; Yi, Jean C; Hamilton, Betty K; Wei, Wei; Preussler, Jaime M; Cerny, Jan; Deol, Abhinav; Jim, Heather; Khera, Nandita; Hahn, Theresa; Hashmi, Shahrukh K; Holtan, Shernan; Jaglowski, Samantha M; Loren, Alison W; McGuirk, Joseph; Reynolds, Jana; Saber, Wael; Savani, Bipin N; Stiff, Patrick; Uberti, Joseph; Wingard, John R; Wood, William A; Baker, K Scott; Majhail, Navneet S; Syrjala, Karen L.
Afiliación
  • Rotz SJ; Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: rotzs@ccf.org.
  • Yi JC; Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington.
  • Hamilton BK; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Wei W; Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Preussler JM; National Marrow Donor Program/Be The Match; Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
  • Cerny J; University of Massachusetts, Chan Medical School, Department of Medicine, Div. of Hematology/Oncology, Worcester, Massachusetts.
  • Deol A; Wayne State University, Karmanos Cancer Institute, Detroit, Michigan.
  • Jim H; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
  • Khera N; Mayo Clinic Arizona, Phoenix, Arizona.
  • Hahn T; Department of Cancer Prevention & Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Hashmi SK; Department of Medicine, SSMC, Abu Dhabi, UAE, Division of Hematology, Department of Medicine, Mayo Clinic, Minnesota.
  • Holtan S; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
  • Jaglowski SM; The Ohio State University, Columbus, Ohio.
  • Loren AW; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • McGuirk J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Westwood, Kansas.
  • Reynolds J; Blood & Marrow Transplant, Baylor University Medical Center, Dallas, Texas.
  • Saber W; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Savani BN; Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Stiff P; Loyola University Stritch School of Medicine, Maywood, Illinois.
  • Uberti J; Wayne State University, Karmanos Cancer Institute, Detroit, Michigan.
  • Wingard JR; University of Florida, Gainesville, Florida.
  • Wood WA; Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Baker KS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Majhail NS; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee.
  • Syrjala KL; Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, Washington.
Transplant Cell Ther ; 28(10): 701.e1-701.e7, 2022 10.
Article en En | MEDLINE | ID: mdl-35872304
ABSTRACT
Young adults (YA), age 18 to 39 years, are at a stage of life that may make them more vulnerable than older adults to impairments in health-related quality of life (HRQOL) during and after hematopoietic cell transplantation (HCT). Health self-efficacy (HSE), the belief that one can implement strategies to produce a desired health outcome, has been associated with health outcomes in oncology research. Little is known about HRQOL or HSE in YA HCT survivors compared with older HCT survivors. Given the age-specific psychosocial challenges facing YA HCT recipients and research on non-transplant YA cancer survivors, we hypothesized that YA survivors would have worse post-HCT HRQOL compared with older adults, and that among YA HCT survivors, higher levels of HSE would be associated with higher levels of HRQOL and lower levels of cancer-related distress. This was a cross-sectional secondary analysis of 2 combined baseline datasets from multicenter studies of HCT survivors approached for participation in clinical trials of survivorship interventions. Participants from 20 transplantation centers in the United States were at 1 to 10 years post-HCT and age ≥18 years at the time of study enrollment, had no evidence of disease relapse/progression or subsequent malignancies, and could read English adequately to consent for and complete assessments. Medical record and patient-reported data were obtained for demographics and HCT-related clinical factors and complications (eg, total body irradiation, chronic graft-versus-host disease [cGVHD]). Participants completed surveys on HRQOL, including the Short-Form [SF]-12, HSE, and Cancer and Treatment Distress (CTXD), which includes 6 subscales and reports an overall mean score. On the SF-12, both the Mental Component Score (MCS) and Physical Component Score (PCS) were calculated. Two cohorts were compared YAs (age 18 to 39 years at transplantation) and older adults (age ≥40 years at transplantation). Multiple linear regression analyses identified factors associated with HSE, PCS, MCS, and CTXD in YAs. In this analysis of 979 survivors, compared with the older adults, the YA participants had lower median mental health scores (SF-12 MCS 48.40 versus 50.23; P = .04) and higher cancer-related distress (CTXD .96 versus .85; P = .04), but better physical health (SF-12 PCS 48.99 versus 47.18; P = .049). Greater overall cancer-related distress was driven by higher levels of uncertainty, financial concern, and medical demand subscales for YAs compared with older adults. Young adults also had lower HSE (2.93 versus 3.08; P = .0004). In a multivariate model, HSE was strongly associated with age group (P = .0005) after adjusting for multiple other transplantation-related factors. Among YAs, HSE was associated with the SF-12 MCS and PCS and the CTXD, and HSE remained significant after adjusting for other transplantation-related factors. Overall, the YA HCT survivors had lower mental health, increased cancer-related distress, and lower levels of HSE compared with the older adults. Although the direction of these effects cannot be determined with these data, the strong association between HSE and HRQOL among YAs suggests that targeting interventions to improve HSE may have broad impact on health outcomes.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Calidad de Vida / Trasplante de Células Madre Hematopoyéticas / Supervivientes de Cáncer Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: America do norte Idioma: En Revista: Transplant Cell Ther Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Calidad de Vida / Trasplante de Células Madre Hematopoyéticas / Supervivientes de Cáncer Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: America do norte Idioma: En Revista: Transplant Cell Ther Año: 2022 Tipo del documento: Article